MedDataX Logo

A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy

NCT ID: NCT00238654

Last Updated: 2011-04-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

257 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-05-31

Study Completion Date

2008-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study has patients responding to two sets of surveys that will tell their doctor or nurse about their readiness to begin self-injection. In addition, patients will have their self-injection observed and evaluated on up to three visits

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone

NCT00240006

Multiple Sclerosis
COMPLETED PHASE4

A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®

NCT00239993

Multiple Sclerosis
COMPLETED PHASE4

Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"

NCT03209479

Multiple Sclerosis
COMPLETED

A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.

NCT00220922

Multiple Sclerosis
COMPLETED PHASE4

The Multicenter, Open-label, Single-use Autoinjector Convenience Study

NCT00958009

Multiple Sclerosis
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or Female, 18 years of age or older, with diagnosis of RRMS
2. Naive to treatment or previously treated with an IFN.

Exclusion Criteria

1. Not eligible for treatment based on clinical criteria and current indication.
2. Unable to respond to surveys or provide informed consent.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Teva Neuroscience, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Teva Neuroscience

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

MerriKay Oleen-Burkey, Ph.D.

Role: STUDY_DIRECTOR

Teva Neuroscience, Inc.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PM08

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis
NCT00203086 COMPLETED
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
NCT01167426 COMPLETED PHASE3
Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe
NCT00915577 COMPLETED PHASE3
Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis
NCT03822858 AVAILABLE
Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline
NCT00203112 COMPLETED PHASE2
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248 RECRUITING PHASE2
Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects
NCT00828204 COMPLETED PHASE3
A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients
NCT00001669 COMPLETED PHASE2
Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®
NCT02499900 COMPLETED PHASE4
Autologous T Cell Vaccine (TCV) for Multiple Sclerosis
NCT00245622 COMPLETED PHASE2
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.
NCT00203073 COMPLETED PHASE2
Avonex PEN Satisfaction and Patients Experience Clinical Trial
NCT01366040 COMPLETED
A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose
NCT00202982 COMPLETED PHASE2
Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects
NCT00292253 COMPLETED PHASE3
A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study
NCT01036165 COMPLETED PHASE3
Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration
NCT01195857 COMPLETED
Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine
NCT00203099 COMPLETED PHASE2
A Pragmatic Trial of Dietary Programs in People With Multiple Sclerosis (MS)
NCT02846558 COMPLETED NA
Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
NCT00203021 COMPLETED PHASE4
Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses
NCT01900093 UNKNOWN NA
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
NCT02284568 COMPLETED PHASE2
Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis
NCT03355365 COMPLETED PHASE2
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
NCT05232825 COMPLETED PHASE3
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
NCT02398461 COMPLETED PHASE1
Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations
NCT01888354 COMPLETED PHASE4